Bevonescein

Summary

Bevonescein (CHEMBL5095488) is a phase-3 clinical-stage small molecule; indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095488
Name	Bevonescein
Type	Small molecule
Max phase	3

Also known as: ALM-488, Bevonescein, Bevonesceina, Bevonesceine, BEVONESCEIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2/PHASE3	1
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05377554	PHASE3	COMPLETED	Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery
NCT06227585	PHASE2/PHASE3	COMPLETED	Feasibility and Efficacy Study for Bevonescein-Assisted Nerve Visualization in Head & Neck Surgery
NCT06662097	PHASE2	RECRUITING	A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery
NCT04420689	PHASE1/PHASE2	COMPLETED	Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).